Oral News and Research

RSS

AB Science announces results from masitinib phase 2 study on MS

AB Science SA, a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors, announces the publication of results from the human phase 2 study of masitinib carried-out in the treatment of progressive multiple sclerosis.

14 Jun 2012

Updated survival data from Takeda’s brentuximab vedotin Phase II trial on HL

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced updated survival data from a pivotal Phase II clinical trial of single-agent brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma (HL) after autologous stem cell transplant (ASCT) showing that the median overall survival has not been reached after a 26.5 month median follow-up.

14 Jun 2012

Innovimmune receives $600,000 NIH grant to develop MIF inhibitors for RA

Specialty drug discovery company, Innovimmune Biotherapeutics, Inc. has been awarded a $600,000 Advanced Technology Small Business Innovation Research Grant from the National Institutes of Health (NIH).

14 Jun 2012

EvaluatePharma releases World Preview 2018 report

EvaluatePharma, the premier provider of pharmaceutical and biotech analysis including consensus forecasts, today released its World Preview 2018 report, providing an in-depth look at how the patent cliff will reshape the drug industry over the next six years — with valuable insight into which companies and products will come out as winners.

14 Jun 2012

EnVivo to present results from EVP-6124 Phase 2b trial on AD at AAIC 2012

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, today announced that the company will present a comprehensive analysis of its recently completed Phase 2b clinical trial of EVP-6124 in Alzheimer's disease at the Alzheimer's Association International Conference 2012 (AAIC), being held July 14-19, 2012 in Vancouver, British Columbia.

14 Jun 2012

Investigational Insomnia Medicine from Merck improved patients’ ability to fall and stay asleep according to new phase III Data

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. The investigational medicine met statistical significance for all primary endpoints except for one measurement at Month 3 in one of the trials. These late-breaking data were presented here today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.

13 Jun 2012

ChromaDex’s pTeroPure safe for human consumption

ChromaDex Corporation, an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries announced today its patented pTeroPure (pterostilbene) was shown to be safe for human consumption according to data from the first clinical trial of the substance.

13 Jun 2012

Compounds related to curcumin receive U.S. patent

A U.S patent issued today to the University of Rochester and two other entities for the use of compounds related to a popular spice in the fight against cancer, acne, baldness, and other medical conditions.

13 Jun 2012

Positive data from Echo's Symphony tCGM System clinical trial on type 1 or 2 diabetes

Echo Therapeutics, Inc., a company developing its needle-free Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude SkinPrep System for transdermal drug delivery, presented an expanded analysis of data collected from subjects with either type 1 or type 2 diabetes during its recent clinical trial of its Symphony tCGM System.

13 Jun 2012

Thiazolidinedione drugs linked with increased risk of DME in patients with Type 2 diabetes

Treatment with glucose-lowering thiazolidinedione drugs in patients with Type 2 diabetes appears to be associated with an increased risk of diabetic macular edema (a complication that may affect vision) at 1-year and 10-year follow-up evaluations, according to a report published Online First by Archives of Internal Medicine, a JAMA Network publication.

12 Jun 2012

Genzyme files LEMTRADA sBLA and MAA with FDA, EMA for treatment of RMS

Genzyme, a Sanofi company, today announced that the company has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval of LEMTRADA (alemtuzumab) for treatment of relapsing multiple sclerosis (RMS).

12 Jun 2012

Investigational drug slows metastatic breast cancer progression

Trastuzumab emtansine significantly delays disease progression compared with standard therapy in women with human epidermal growth factor receptor-2-positive metastatic breast cancer, show study data presented at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, USA.

11 Jun 2012

Dapagliflozin more effective than sitagliptin for adult patients with type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced results from a Phase 3 clinical study that showed the investigational compound dapagliflozin 10 mg demonstrated significant reductions in blood sugar levels (glycosylated hemoglobin levels, or HbA1c) compared with placebo at 24 weeks when either agent was added to existing sitagliptin therapy (with or without metformin) in adult patients with type 2 diabetes.

11 Jun 2012

Incyte, Lilly announce 12-week results from baricitinib Phase IIb study on RA

Eli Lilly and Company and Incyte Corporation announced the presentation of 12-week results from a Phase IIb study of baricitinib, formerly LY3009104 (INCB28050), an orally available janus kinase (JAK) inhibitor, in patients with active rheumatoid arthritis.

11 Jun 2012

Positive results from Amgen Sensipar/Mimpara Phase 3 trial for HPT, CKD

Amgen today announced top-line results of the Phase 3 EVOLVE (EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events) trial, which evaluated Sensipar/Mimpara (cinacalcet) for the reduction of the risk of mortality and cardiovascular (CV) events among 3,883 patients with secondary hyperparathyroidism (HPT) and chronic kidney disease (CKD) receiving dialysis.

8 Jun 2012

What are vitamins?

Most people have heard of vitamin C and its effects upon the body; but how much do you know about other vitamins? How many even are there? And what do they all do?

8 Jun 2012

Patients over 45 years with history of early menopause 50% less likely to develop severe RA

A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that early menopause predicts a milder form of rheumatoid arthritis (RA).

8 Jun 2012

Pneumonia and diarrhoea remain biggest killers of East Asia-Pacific children

A new report from UNICEF has highlighted the huge child survival gap between the richest and the poorest children by focusing on pneumonia and diarrhoea – the two primary killers of children under the age of five.

8 Jun 2012

Strand, Trovagene enter MOU to license and validate HPV assay technology

Trovagene, Inc., a developer of trans-renal molecular diagnostics, and Strand Life Sciences Pvt Ltd., of Bangalore, India, have entered into a Memorandum of Understanding (MOU) to license and validate Trovagene's proprietary Human Papillomavirus (HPV) urine test and High Risk HPV DNA Assay for clinical diagnostic and carrier screening use in India and countries in the South Asian Association for Regional Cooperation.

8 Jun 2012

Clinical study demonstrates effectiveness of vismodegib in treating BCNS

A revolutionary clinical study has demonstrated the effectiveness of a new drug, vismodegib, in dramatically shrinking and preventing the formation of basal cell skin cancers - the most common cancer in the United States - in patients with basal cell nevus syndrome (BCNS), a rare genetic condition that causes hundreds to thousands of skin cancers primarily treated by surgical removal.

7 Jun 2012